Remus PharmaceuticalsNSE:REMUS -2.72%55 EV-to-FCF is 251.55 as of Jul. 09, 2026, which is 49% above its 10-year median of 169.04. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 74 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 94.59% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Remus Pharmaceuticals's Enterprise Value is ₹9,031 Mil.
Remus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹36 Mil. Therefore, Remus Pharmaceuticals's EV-to-FCF for today is 251.55.
The historical rank and industry rank for Remus Pharmaceuticals's EV-to-FCF or its related term are showing as below:
NSE:REMUS'
s EV-to-FCF Range Over the Past 10 Years
Min: -797.06 Med: 169.04 Max: 335.46
Current: 254.37
During the past 7 years, the highest EV-to-FCF of Remus Pharmaceuticals was 335.46. The lowest was -797.06. And the median was 169.04.
NSE:REMUS's EV-to-FCF is ranked worse than 94.59% of 74
companies
in the Medical Distribution industry
Industry Median: 17.235
vs NSE:REMUS: 254.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Remus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Remus Pharmaceuticals's share price for today is ₹758.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹39.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Remus Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's EV-to-FCF falls into.
Remus Pharmaceuticals's current Enterprise Value is ₹9,031 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a EV-to-FCF of 251.55 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Remus Pharmaceuticals and its competitors. This is 49% above median its historical median of 169.04. According to the industry distribution chart, Remus Pharmaceuticals ranks #70 out of 74 companies in the Medical Distribution industry, placing it in the top 94.6%.
Is Remus Pharmaceuticals' EV-to-FCF too high?
Remus Pharmaceuticals' current EV-to-FCF of 251.55 is 49% above median its 10-year median of 169.04. The Medical Distribution industry median EV-to-FCF is 17.24. Remus Pharmaceuticals' value of 251.55 is 1359.5% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #70 out of 74 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' EV-to-FCF compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #70 out of 74 companies for EV-to-FCF. This places Remus Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 17.24. Remus Pharmaceuticals' value of 251.55 is 1359.5% above this benchmark. While the company's 10-year median is 169.04 vs. the industry median of 17.24, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.24, based on 74 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current EV-to-FCF of 251.55 is 1359.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current EV-to-FCF is 251.55, which is 49% above median its own 10-year median of 169.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹758.80 — trading 63.4% below its estimated fair value. The current EV-to-FCF is 251.55, which is 49% above median its 10-year median of 169.04 and 1359.5% above the Medical Distribution industry median of 17.24. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current EV-to-FCF is 251.55 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹758.80 is trading 63.4% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
EV-to-FCF: 251.55 (49% above median its 10-year median of 169.04)
GF Value™: ₹2,071.36 vs. price of ₹758.80 (63.4% below fair value)
Industry Position: 1359.5% above the Medical Distribution median (#70 of 74)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
